Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTirzepatide (Mounjaro) has a half-life of roughly five days, which means it takes around four to five weeks for it to clear your system entirely after your last injection. That timeline matters whether you are planning surgery, thinking about pregnancy, switching medicines, or simply curious about what happens when you stop. As a prescription-only medicine, any decision about stopping or pausing Mounjaro should be discussed with your prescriber rather than made alone. The sections below walk through exactly how the clearance process unfolds, week by week.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Once you miss or take your final dose of Mounjaro, the drug's concentration in your bloodstream begins falling immediately. Tirzepatide's half-life sits at roughly five days, which is unusually long for an injectable medicine. By the end of the first week, levels are noticeably lower but still substantial, roughly half of your last peak concentration remains. You may notice appetite starting to creep back during this window, though most people describe it as gradual rather than sudden. Some mild changes in digestion are common too: the slowing effect Mounjaro has on gastric emptying starts to reverse, which can feel strange after weeks or months of a quieter stomach. There is a common misconception that stopping any injection medicine means it is gone within days, with tirzepatide, that is not the case. If you are curious about how long Mounjaro is actually in your system, the pharmacokinetics are set by the molecule itself, and no amount of extra water or activity speeds the process up meaningfully. The Mounjaro overview page explains how the medicine works in more detail if you want the mechanism behind this.
Between around day seven and day twenty-one, plasma tirzepatide continues to decline steadily. Each five-day half-life removes roughly half of whatever remains, so progress is logarithmic: fast at first, then slower. By the end of week two, levels are typically around 25% of the last trough concentration. By the end of week three, you are approaching 10–12%. At this point the physiological effects (appetite suppression, slowed gastric emptying, the dual GIP and GLP-1 receptor signalling) are significantly reduced but not yet absent. This is also the phase where many people notice hunger returning more noticeably. Calorie intake often rises, and without active attention to the dietary habits built during treatment, weight can begin to creep back. Research from the broader SURMOUNT-1 trial, published in the New England Journal of Medicine, showed that participants who stopped tirzepatide regained a portion of lost weight over the following year, underscoring that the drug's presence is doing real physiological work during this phase. If you are switching to a different treatment, your prescriber will use this window to time the transition carefully, and our page on how long until Mounjaro is out of your system can help you understand exactly what that timeline looks like. See the clearance summary page for a condensed version of this schedule.
By day 28–35 after the last injection, tirzepatide is at or below the threshold considered clinically significant. This is the window most commonly used as a planning marker for specific decisions. For surgical procedures, NHS England advises patients to inform their anaesthetist and surgical team that they are taking a GLP-1 medicine, and the residual slowed gastric emptying during this phase is one reason clinicians need advance notice, a full month's notice is commonly requested. For anyone thinking about pregnancy, our detailed guide on how long before Mounjaro is out of your system covers the wash-out period you should allow before trying to conceive; the exact timing should be confirmed with your prescriber, who will also advise on contraception in the interim. The NHS tirzepatide medicines page provides patient-level detail on what to do in these situations. If you are weighing the longer-term cost picture of staying on treatment versus pausing, the Mounjaro cost page gives a factual overview of what private treatment involves financially.
Here is a practically important point that does not get enough attention: the drug leaving your body does not reset everything you achieved. Muscle retained during treatment, habits built around food, and any improvements in blood sugar or blood pressure may persist well beyond the clearance window, especially if lifestyle changes have become genuinely embedded. What does tend to reverse, for many people, is the suppression of appetite. Hunger-regulating hormones shift back toward pre-treatment patterns fairly quickly once tirzepatide is gone. How quickly, and how pronounced, varies person to person. Some find the return gradual and manageable; for others it is more abrupt. Neither experience is a failure. If you are concerned about what stopping means for your progress, that conversation is worth having before you stop, not after. Our prescribers can talk through your options, including whether a pause or a planned step-down makes more sense than a clean stop. If you have questions about timing, or anything else about your treatment journey, you can also browse the FAQs or reach the team through the contact page. When you are ready to discuss your next steps properly, speak to our prescribers through a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.